

## Special Issue

# Neoadjuvant Treatments in Breast Cancer Patients

### Message from the Guest Editors

Neoadjuvant therapy is the mainstay of treatment for locally advanced breast cancer. It provides an increasingly appealing alternative to the surgical approach in patients with primary operable disease. Of note, neoadjuvant treatment may represent an adequate alternative for surgical de-escalation in patients suitable for complete resection at initial diagnosis. In this context, neoadjuvant therapy could lead to the conversion from mastectomy to breast-conserving therapies, reduce volume resection in breast-conserving surgery, and allow for a minimally invasive axillary management. More recently, neoadjuvant strategies have gained additional strengths. The available armamentarium has considerably widened through the use of innovative, highly efficacious drugs, such as taxanes, dual anti-Her-2 blockade, and immunotherapy.

---

### Guest Editors

Dr. Laura Pizzuti

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Roma, Italy

Dr. Maddalena Barba

Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Roma, Italy

---

### Deadline for manuscript submissions

closed (1 July 2021)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/si/54126](https://mdpi.com/si/54126)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 9.0  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)